December 25, 2024 - 08:08

NexPoint Real Estate Finance, Inc. has officially announced a dividend for its 8.50% Series A Cumulative Redeemable Preferred Stock. This decision reflects the company's ongoing commitment to providing value to its shareholders. The dividend will be payable to stockholders of record as of a specified date, ensuring that those who have invested in the Series A preferred stock will receive their due returns.
The announcement highlights the company's strong financial position and its ability to generate consistent income for its investors. This dividend is part of NexPoint's strategy to maintain investor confidence and attract potential shareholders looking for stable returns in the real estate finance sector.
As the market continues to evolve, NexPoint remains focused on its investment strategy, which aims to capitalize on opportunities within the real estate market. The declaration of this dividend underscores the company’s dedication to delivering shareholder value while navigating the complexities of the financial landscape.
November 12, 2025 - 19:08
Aeluma Reports Strong Financial Performance for First Quarter of Fiscal 2026Aeluma, Inc., a leading semiconductor company known for its innovative high-performance technologies, has announced its financial results for the first quarter of fiscal 2026, which concluded on...
November 12, 2025 - 07:43
Celebrating Excellence: Winners of the 2025 US Women in Finance AwardsThe 2025 US Women in Finance Awards have recognized outstanding contributions from women leaders in the financial sector. Among the notable winners, Mitali Sohoni from Citi has been honored for her...
November 11, 2025 - 19:48
Key Metrics to Monitor in Disney's Upcoming Earnings ReportDisney is set to release its earnings report on Thursday, marking a significant moment as it will disclose subscriber numbers for the last time. Analysts are keenly focused on three critical...
November 11, 2025 - 01:05
ProKidney Announces Q3 2025 Financial Outcomes and Key DevelopmentsProKidney has released its financial results for the third quarter of 2025, highlighting significant progress in its clinical studies and regulatory endeavors. The company recently showcased full...